๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II study of trimetrexate in malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group Study

โœ Scribed by Neill A. Iscoe; Elizabeth A. Eisenhauer; Audley J. Bodurtha

Publisher
Springer US
Year
1990
Tongue
English
Weight
183 KB
Volume
8
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

โœฆ Synopsis

The National Cancer Institute of Canada Clinical Trials Group carried out a phase II trial of trimetrexate given in a daily x 5 intravenous bolus schedule every 3 weeks in patients with measurable metastatic malignant melanoma who had not received previous chemotherapy. Significant hematologic toxicity was observed and was not obviously related to the dose of trimetrexate. No responses were seen in 18 patients. We did not find trimetrexate given as described to be effective in metastatic malignant melanoma.

๐Ÿ“œ SIMILAR VOLUMES

Phase II study of flutamide in patients
Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study
โœ Daniele J. Perrault; Diane M. Logan; David J. Stewart; Vivien H. C. Bramwell; Al ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› Springer US ๐ŸŒ English โš– 271 KB

The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study of the oral antiandrogen flutamide in 33 patients with metastatic breast cancer. Eight patients had received no prior systemic therapy for their metastatic disease and 13 had only one site of metastasis.

Treatment of metastatic malignant melano
Treatment of metastatic malignant melanoma with trimetrexate: A phase II study
โœ Odujinrin, Oluwole ;Goldberg, David ;Doroshow, James ;Leong, Lucille ;Margolin, ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 361 KB

## Abstract Trimetrexate glucuronate, a nonclassical antifolate, was administered to 14 patients with recurrent and progressive metastatic malignant melanoma. Thirteen patients were evaluable for response and toxicity. Five patients had received prior treatment consisting of immunotherapy (one pati

Venous thromboembolism and nonsmall cell
Venous thromboembolism and nonsmall cell lung cancer : A pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials
โœ Lisa K. Hicks; Matthew C. Cheung; Keyue Ding; Baktiar Hasan; Lesley Seymour; Aur ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 174 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND: Advanced nonsmall cell lung cancer (NSCLC) is associated with venous thromboembolism (VTE). However, to the authors' knowledge, the incidence of VTE in early NSCLC, predictors of VTE, and the prognostic significance of VTE in NSCLC have not been explored. ## METHODS: I